📊 VXRT Key Takeaways
Is Vaxart, Inc. (VXRT) a Good Investment?
Vaxart demonstrates exceptional revenue growth (726.7% YoY) and reported profitability, but faces a critical red flag: operating cash flow of $7.7M represents only 47% of reported net income ($16.3M), suggesting significant earnings quality concerns or unsustainable revenue recognition. The biotech company maintains a healthy balance sheet with 0.20x debt/equity and $53.8M cash, but the massive disconnect between reported earnings and actual cash generation requires urgent clarification before any bullish stance is justified.
Why Buy Vaxart, Inc. Stock? VXRT Key Strengths
- Exceptional revenue growth of 726.7% YoY with positive net income ($16.3M) and operating income ($18.1M)
- Conservative capital structure with 0.20x debt/equity ratio and strong $53.8M cash position (29% of assets)
- Solid liquidity metrics (1.57x current ratio) and reasonable returns (18.6% ROE, 8.8% ROA)
VXRT Stock Risks: Vaxart, Inc. Investment Risks
- Critical earnings quality concern: operating cash flow ($7.7M) is only 47% of net income ($16.3M), indicating potential accounting issues or aggressive revenue recognition
- Extremely thin free cash flow margin (3.2%) despite 7.6% operating margin suggests minimal actual cash generation from massive revenue base
- Missing gross margin data prevents verification of core product profitability; biotech sector regulatory and R&D execution risks
Key Metrics to Watch
- Operating cash flow trend and cash conversion rate relative to net income
- Revenue composition and sustainability (government contracts vs. commercial sales)
- Accounts receivable and working capital changes driving OCF/earnings disconnect
Vaxart, Inc. (VXRT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 3.2% FCF margin may limit capital allocation flexibility.
VXRT Profit Margin, ROE & Profitability Analysis
VXRT vs Healthcare Sector: How Vaxart, Inc. Compares
How Vaxart, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vaxart, Inc. Stock Overvalued? VXRT Valuation Analysis 2026
Based on fundamental analysis, Vaxart, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vaxart, Inc. Balance Sheet: VXRT Debt, Cash & Liquidity
VXRT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vaxart, Inc.'s revenue has declined by 25% over the 5-year period, indicating business contraction. The most recent EPS of $-0.33 indicates the company is currently unprofitable.
VXRT Revenue Growth, EPS Growth & YoY Performance
VXRT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.9M | -$8.1M | $-0.04 |
| Q2 2025 | $6.4M | -$15.0M | $-0.07 |
| Q1 2025 | $2.2M | -$15.6M | $-0.07 |
| Q3 2024 | $2.1M | -$14.1M | $-0.06 |
| Q2 2024 | $1.4M | -$16.5M | $-0.09 |
| Q1 2024 | $675.0K | -$24.4M | $-0.14 |
| Q3 2023 | N/A | -$17.4M | $-0.11 |
| Q2 2023 | N/A | -$22.6M | $-0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vaxart, Inc. Dividends, Buybacks & Capital Allocation
VXRT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vaxart, Inc. (CIK: 0000072444)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VXRT
What is the AI rating for VXRT?
Vaxart, Inc. (VXRT) has an AI rating of HOLD with 48% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VXRT's key strengths?
Claude: Exceptional revenue growth of 726.7% YoY with positive net income ($16.3M) and operating income ($18.1M). Conservative capital structure with 0.20x debt/equity ratio and strong $53.8M cash position (29% of assets).
What are the risks of investing in VXRT?
Claude: Critical earnings quality concern: operating cash flow ($7.7M) is only 47% of net income ($16.3M), indicating potential accounting issues or aggressive revenue recognition. Extremely thin free cash flow margin (3.2%) despite 7.6% operating margin suggests minimal actual cash generation from massive revenue base.
What is VXRT's revenue and growth?
Vaxart, Inc. reported revenue of $237.3M.
Does VXRT pay dividends?
Vaxart, Inc. does not currently pay dividends.
Where can I find VXRT SEC filings?
Official SEC filings for Vaxart, Inc. (CIK: 0000072444) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VXRT's EPS?
Vaxart, Inc. has a diluted EPS of $0.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VXRT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Vaxart, Inc. has a HOLD rating with 48% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VXRT stock overvalued or undervalued?
Valuation metrics for VXRT: ROE of 18.6% (sector avg: 15%), net margin of 6.9% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy VXRT stock in 2026?
Our dual AI analysis gives Vaxart, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VXRT's free cash flow?
Vaxart, Inc.'s operating cash flow is $7.7M, with capital expenditures of $145.0K. FCF margin is 3.2%.
How does VXRT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 6.9% (avg: 12%), ROE 18.6% (avg: 15%), current ratio 1.57 (avg: 2).